Primary vaginal cancer — originating in the vaginal wall itself — is among the rarest gynaecological malignancies, accounting for fewer than 2% of all gynaecological cancers. The vast majority of vaginal malignancies are secondary (metastatic), most commonly from cervical, endometrial, or vulvar cancer, or from distant primary sites. Because primary vaginal cancer is so uncommon, it requires management by a specialist gynaecological oncologist with experience in this specific disease.
Dr. Nishtha Tripathi Patel manages vaginal cancer as part of her specialist gynaecological oncology practice in Ahmedabad. Diagnosis, staging, and treatment — whether surgical, radiotherapeutic, or combined — are coordinated within a multidisciplinary oncology team.
Trust Signals
- Specialty: Gynecologic Oncology
Types of Vaginal Cancer
- Squamous cell carcinoma (SCC) — accounts for approximately 85–90% of primary vaginal cancers. Most strongly associated with HPV infection (particularly HPV 16). Often develops in the posterior wall of the upper third of the vagina — the area most directly adjacent to the cervix.
- Adenocarcinoma — accounts for ~10% of vaginal cancers. A rare subtype, clear cell adenocarcinoma, is associated with in utero exposure to diethylstilboestrol (DES), a synthetic oestrogen used in pregnant women before 1971. DES-associated clear cell vaginal cancer typically presents in younger women.
- Vaginal melanoma — extremely rare. Arises from melanocytes in the vaginal mucosa. Prognosis is poor because it is usually diagnosed at an advanced stage.
- Vaginal intraepithelial neoplasia (VAIN) — pre-cancerous changes of the vaginal epithelium, analogous to CIN of the cervix. Detected on colposcopy after abnormal Pap smear. VAIN 3 (high-grade dysplasia) may progress to invasive cancer if untreated.
Risk Factors and Symptoms
Risk factors:
- Persistent HPV infection (same high-risk HPV strains as cervical cancer)
- Prior history of cervical cancer or CIN treated with hysterectomy (VAIN and vaginal cancer can develop in the vaginal cuff after hysterectomy)
- Prior pelvic radiotherapy
- In utero DES exposure (for clear cell adenocarcinoma)
- Immunosuppression
- Age over 60 (most primary vaginal cancers occur in postmenopausal women)
Symptoms:
- Painless postmenopausal bleeding or abnormal vaginal bleeding
- Blood-stained or malodorous vaginal discharge
- A mass or lump felt in the vagina
- Pain during sexual intercourse (dyspareunia)
- Pelvic or perineal pain
- Difficulty or pain with urination (if bladder is involved)
- Rectal tenesmus or bleeding (if rectal wall is involved)
Many early vaginal lesions are asymptomatic and detected on colposcopy performed for abnormal cervical screening. Annual gynaecological examination (including speculum exam of the vaginal walls) is important, particularly for women who have had a hysterectomy for CIN or cervical cancer.
Diagnosis and Staging (FIGO)
Diagnosis:
- Speculum examination — direct visualisation of the vaginal walls; a lesion in the vagina with no evidence of cervical or vulvar primary confirms primary vaginal origin.
- Colposcopy — for evaluation of abnormal areas, particularly following abnormal cervical screening in women who have had a hysterectomy.
- Punch biopsy — tissue confirmation from the lesion under direct visualisation.
- MRI pelvis — assesses tumour size, depth of invasion into vaginal wall, bladder/rectal involvement, and lymph node status. Essential for staging and planning radiotherapy fields.
- PET-CT — for assessment of nodal and distant spread, particularly before radiotherapy planning.
FIGO staging:
- Stage I — tumour confined to the vaginal wall
- Stage II — tumour invades subvaginal tissues but has not extended to the pelvic wall
- Stage III — tumour extends to the pelvic wall
- Stage IVA — tumour invades bladder or rectal mucosa, or extends beyond the true pelvis
- Stage IVB — distant metastasis
Treatment
Treatment is highly individualised based on tumour location, size, stage, patient age, and whether the patient has had a prior hysterectomy. A multidisciplinary discussion with gynaecological oncology, radiation oncology, and medical oncology is essential.
- Surgery for early disease (Stage I) — wide local excision or partial vaginectomy for small, accessible Stage I tumours, particularly in the upper vagina. For posterior upper vaginal tumours, radical hysterectomy, upper vaginectomy, and pelvic lymphadenectomy may be performed. Surgery is more commonly used for upper-third lesions where margins can be achieved without compromising continence or sexual function.
- Radiotherapy — the primary modality for most vaginal cancers — external beam radiotherapy (EBRT) to the pelvis combined with intracavitary or interstitial brachytherapy (BRT). The dose to the vaginal tumour via brachytherapy can be precisely delivered while sparing adjacent bladder and rectum. For Stage IB and above, chemoradiotherapy (concurrent cisplatin with EBRT) is standard.
- VAIN (pre-cancer) treatment — options include topical 5-fluorouracil cream, laser ablation, surgical excision, and intravaginal brachytherapy depending on extent and grade of VAIN.
- Systemic chemotherapy — for metastatic or recurrent disease; platinum-based regimens with or without immunotherapy (pembrolizumab for PD-L1–positive tumours).
Treatment planning is guided by Dr. Nishtha Tripathi Patel, Consultant Gynecological Oncosurgeon in Ahmedabad.
Consultation available in Ahmedabad, Surat, Vadodara, and Gandhinagar.
Frequently Asked Questions
- How is vaginal cancer different from cervical cancer?
Both vaginal and cervical cancer share a common cause (high-risk HPV infection) and many risk factors, but they arise in different locations. Cervical cancer originates at the cervix (the lower end of the uterus), while primary vaginal cancer arises from the vaginal wall itself with no involvement of the cervix at the outset. The distinction between a primary vaginal cancer and a secondary (metastatic) cancer from the cervix or endometrium requires careful clinical evaluation and sometimes imaging. Treatment approaches also differ: early cervical cancer is primarily managed surgically, whereas most vaginal cancers are managed with radiotherapy.
- Can vaginal cancer develop after a hysterectomy?
Yes. Women who have had a hysterectomy for cervical cancer or CIN retain the vaginal vault and can develop vaginal intraepithelial neoplasia (VAIN) or primary vaginal cancer. The risk is highest in women who had their hysterectomy for high-grade CIN or early cervical cancer, as the same HPV-related field defect that affected the cervix can involve the vaginal epithelium. Annual vaginal vault cytology (vault smear) is recommended for women who had a hysterectomy for CIN 3 or cervical cancer — indefinitely or for at least 10 years depending on local guidelines.
- Is vaginal cancer curable?
Early-stage vaginal cancer (Stage I) treated with surgery or radiotherapy has a five-year survival rate of 70–85%. Overall survival rates are lower than for cervical or endometrial cancer partly because vaginal cancer is often diagnosed at a more advanced stage due to lack of awareness. VAIN (pre-cancer) is essentially curable with appropriate local treatment. Prognosis worsens significantly for Stage III–IV disease, though chemoradiotherapy can achieve durable remission in some patients.
- What is DES-related vaginal cancer?
Diethylstilboestrol (DES) was a synthetic oestrogen given to pregnant women between the 1940s and 1971 to prevent miscarriage. Women whose mothers took DES during pregnancy (“DES daughters”) have a small but increased risk of clear cell adenocarcinoma of the vagina, typically presenting between the ages of 15 and 30. This risk, though real, is very small — approximately 1 in 1,000 DES daughters. DES daughters should have regular gynaecological examinations including careful inspection of the vaginal walls. DES is no longer used in pregnancy anywhere in the world.